Macy Martinson, MD
Nephrology · Hilo, HINPI 1881919348
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $340 of the $392 with a category attached, or 86.7%. 10 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 34.3% of the total. Reporting peaked in 2024 at $168 and has fallen 51.3% since, to $82 in 2025. That places this record below the midpoint for nephrology clinicians in HI, where the typical reported total is $2,126.
Across 17 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$134
- Ardelyx, Inc.$43
- Vifor Pharma, Inc.$43
- Amgen$38
- Mallinckrodt Hospital Products Inc.$33
- Masimo Corporation$27
- plus $73 from 4 others
Across 27 payments — averaging $1152.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$31K
What the payments were for
- Food & beverage$34087%
- Education$5213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 1 | $134 |
| Ardelyx, Inc. | 2 | $43 |
| Vifor Pharma, Inc. | 3 | $43 |
| Amgen | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Masimo Corporation | 1 | $27 |
| Bayer | 1 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Travere Therapeutics, Inc. | 4 | $8 |
How this compares
$392 in reported general payments places this provider in the 20th percentile of 57 nephrology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 46 | $46,546 |
| FarxigaDapagliflozin Propanediol | 13 | $15,141 |
| Sevelamer Carbonate | 16 | $6,133 |
| Potassium Chloride | 25 | $1,386 |
| Losartan Potassium | 48 | $922 |
| Amlodipine Besylate | 76 | $827 |
| Calcium Acetate | 14 | $595 |
| Hydralazine Hcl | 23 | $401 |
| Nifedipine ErNifedipine | 13 | $315 |
| Allopurinol | 27 | $259 |
| Furosemide | 25 | $235 |
| Calcitriol | 25 | $201 |
| Lisinopril | 32 | $181 |
| Carvedilol | 17 | $170 |
| Atorvastatin Calcium | 12 | $32 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Hilo
- Curtis LeeHilo$17K
- Kunal ParekhHonolulu$172K
- Christie IzutsuHonolulu$50K
- Jared SugiharaHonolulu$39K
- Eugene WongHonolulu$37K
- Shiuh ChengHonolulu$21K
- Valerie TanWaipahu$15K
- Leilani Ka'aneheHonolulu$10K
- Antonette Veronica HernandezHonolulu$9K
- Rick HayashiHonolulu$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.